|
1
|
Marczak A and Denel M: Trabectedin as a
single agent and in combination with pegylated liposomal
doxorubicin-activity against ovarian cancer cells. Contemp Oncol
(Pozn). 18:149–152. 2014.
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karst AM and Drapkin R: The new face of
ovarian cancer modeling: Better prospects for detection and
treatment. F1000 Med Rep. 3:222011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liotta LA, Steeg PS and Stetler-Stevenson
WG: Cancer metastasis and angiogenesis: An imbalance of positive
and negative regulation. Cell. 64:327–336. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang C and Werb Z: The many faces of
metalloproteases: Cell growth, invasion, angiogenesis and
metastasis. Trends Cell Biol. 11:S37–S43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tanimoto H, Underwood LJ, Wang Y,
Shigemasa K, Parmley TH and O'Brien TJ: Ovarian tumor cells express
a transmembrane serine protease: A potential candidate for early
diagnosis and therapeutic intervention. Tumour Biol. 22:104–114.
2001. View Article : Google Scholar
|
|
7
|
Takeuchi T, Shuman MA and Craik CS:
Reverse biochemistry: Use of macromolecular protease inhibitors to
dissect complex biological processes and identify a membrane-type
serine protease in epithelial cancer and normal tissue. Proc Natl
Acad Sci USA. 96:11054–11061. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Szabo R and Bugge TH: Type II
transmembrane serine proteases in development and disease. Int J
Biochem Cell Biol. 40:1297–1316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin CY, Anders J, Johnson M, Sang QA and
Dickson RB: Molecular cloning of cDNA for matriptase, a
matrix-degrading serine protease with trypsin-like activity. J Biol
Chem. 274:18231–18236. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanimoto H, Shigemasa K, Tian X, Gu L,
Beard JB, Sawasaki T and O'Brien TJ: Transmembrane serine protease
TADG-15 (ST14/Matriptase/MT-SP1): Expression and prognostic value
in ovarian cancer. Br J Cancer. 92:278–283. 2005.
|
|
11
|
Nakamura K, Hongo A, Kodama J, Abarzua F,
Nasu Y, Kumon H and Hiramatsu Y: Expression of matriptase and
clinical outcome of human endometrial cancer. Anticancer Res.
29:1685–1690. 2009.PubMed/NCBI
|
|
12
|
Szabo R, Rasmussen AL, Moyer AB, Kosa P,
Schafer JM, Molinolo AA, Gutkind JS and Bugge TH: c-Met-induced
epithelial carcinogenesis is initiated by the serine protease
matriptase. Oncogene. 30:2003–2016. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jin JS, Hsieh DS, Loh SH, Chen A, Yao CW
and Yen CY: Increasing expression of serine protease matriptase in
ovarian tumors: Tissue microarray analysis of immunostaining score
with clinicopathological parameters. Mod Pathol. 19:447–452. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Benaud C, Dickson RB and Lin CY:
Regulation of the activity of matriptase on epithelial cell
surfaces by a blood-derived factor. Eur J Biochem. 268:1439–1447.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oberst MD, Johnson MD, Dickson RB, Lin CY,
Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H and
Sellar GC: Expression of the serine protease matriptase and its
inhibitor HAI-1 in epithelial ovarian cancer: Correlation with
clinical outcome and tumor clinicopathological parameters. Clin
Cancer Res. 8:1101–1107. 2002.PubMed/NCBI
|
|
16
|
Vogel LK, Saebø M, Skjelbred CF, Abell K,
Pedersen ED, Vogel U and Kure EH: The ratio of Matriptase/HAI-1
mRNA is higher in colorectal cancer adenomas and carcinomas than
corresponding tissue from control individuals. BMC Cancer.
6:1762006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang ZQ, Chen XF, Sun PM, Mao XD, Lin F
and Song YY: Expression and significance of matriptase in ovarian
cancer cells with diverse metastatic potential. Zhonghua Fu Chan Ke
Za Zhi. 48:370–374. 2013.In Chinese. PubMed/NCBI
|
|
18
|
Mou HZ, Xu SH and Zhang YY: The
establishment of human ovarian carcinoma cell line HO-8910 and its
characteristics. Zhonghua Fu Chan Ke Za Zhi. 29:162–164. 1911994.In
Chinese.
|
|
19
|
Xu S, Mou H, Lü G, Zhu C, Yang Z, Gao Y,
Lou H, Liu X, Cheng Y and Yang W: Gene expression profile
differences in high and low metastatic human ovarian cancer cell
lines by gene chip. Chin Med J (Engl). 115:36–41. 2002.
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Rosnoblet C, Legrand D, Demaegd D,
Hacine-Gherbi H, de Bettignies G, Bammens R, Borrego C, Duvet S,
Morsomme P, Matthijs G and Foulquier F: Impact of disease-causing
mutations on TMEM165 subcellular localization, a recently
identified protein involved in CDG-II. Hum Mol Genet. 22:2914–2928.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa
P, Gui Y and Cai Z: Synthetic miRNA-mowers targeting miR-183-96-182
cluster or miR-210 inhibit growth and migration and induce
apoptosis in bladder cancer cells. PloS One. 7:e522802012.
View Article : Google Scholar
|
|
23
|
Qi S, Song Y, Peng Y, Wang H, Long H, Yu
X, Li Z, Fang L, Wu A, Luo W, et al: ZEB2 mediates multiple
pathways regulating cell proliferation, migration, invasion and
apoptosis in glioma. PloS One. 7:e388422012. View Article : Google Scholar
|
|
24
|
Yu LL, Chang K, Lu LS, Zhao D, Han J,
Zheng YR, Yan YH, Yi P, Guo JX, Zhou YG, et al: Lentivirus-mediated
RNA interference targeting the H19 gene inhibits cell proliferation
and apoptosis in human choriocarcinoma cell line JAR. BMC Cell
Biol. 14:262013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
List K: Matriptase: A culprit in cancer?
Future Oncol. 5:97–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sanders AJ, Parr C, Davies G, Martin TA,
Lane J, Mason MD and Jiang WG: Genetic reduction of matriptase-1
expression is associated with a reduction in the aggressive
phenotype of prostate cancer cells in vitro and in vivo. J Exp Ther
Oncol. 6:39–48. 2006.
|
|
28
|
Chou FP, Xu H, Lee MS, Chen YW, Richards
OX, Swanson R, Olson ST, Johnson MD and Lin CY: Matriptase is
inhibited by extravascular antithrombin in epithelial cells but not
in most carcinoma cells. Am J Physiol Cell Physiol.
301:C1093–C1103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee SL, Dickson RB and Lin CY: Activation
of hepatocyte growth factor and urokinase/plasminogen activator by
matriptase, an epithelial membrane serine protease. J Biol Chem.
275:36720–36725. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suzuki M, Kobayashi H, Kanayama N, Saga Y,
Suzuki M, Lin CY, Dickson RB and Terao T: Inhibition of tumor
invasion by genomic down-regulation of matriptase through
suppression of activation of receptor-bound pro-urokinase. J Biol
Chem. 279:14899–14908. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen C, Sun MZ, Liu S, Yeh D, Yu L, Song
Y, Gong L, Hao L, Hu J and Shao S: Smad4 mediates malignant
behaviors of human ovarian carcinoma cell through the effect on
expressions of E-cadherin, plasminogen activator inhibitor-1 and
VEGF. BMB Rep. 43:554–560. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dong PX, Jia N, Xu ZJ, Liu YT, Li DJ and
Feng YJ: Silencing of IQGAP1 by shRNA inhibits the invasion of
ovarian carcinoma HO-8910PM cells in vitro. J Exp Clin Cancer Res.
27:772008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Köbel M, Kalloger SE, Boyd N, McKinney S,
Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al:
Ovarian carcinoma subtypes are different diseases: Implications for
biomarker studies. PLoS Med. 5:e2322008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Parr C, Watkins G, Mansel RE and Jiang WG:
The hepatocyte growth factor regulatory factors in human breast
cancer. Clin Cancer Res. 10:202–211. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kang JY, Dolled-Filhart M, Ocal IT, Singh
B, Lin CY, Dickson RB, Rimm DL and Camp RL: Tissue microarray
analysis of hepatocyte growth factor/Met pathway components reveals
a role for Met, matriptase and hepatocyte growth factor activator
inhibitor 1 in the progression of node-negative breast cancer.
Cancer Res. 63:1101–1105. 2003.PubMed/NCBI
|
|
36
|
Kosa P, Szabo R, Molinolo AA and Bugge TH:
Suppression of tumorigenicity-14, encoding matriptase, is a
critical suppressor of colitis and colitis-associated colon
carcinogenesis. Oncogene. 31:3679–3695. 2012. View Article : Google Scholar :
|
|
37
|
Sun PM, Wei LH, Luo MY, Liu G, Wang JL,
Mustea A, Könsgen D, Lichtenegger W and Sehouli J: The telomerase
activity and expression of hTERT gene can serve as indicators in
the anti-cancer treatment of human ovarian cancer. Eur J Obstet
Gynecol Reprod Biol. 130:249–257. 2007. View Article : Google Scholar
|
|
38
|
Welman A, Sproul D, Mullen P, Muir M,
Kinnaird AR, Harrison DJ, Faratian D, Brunton VG and Frame MC:
Diversity of matriptase expression level and function in breast
cancer. PloS One. 7:e341822012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tripathi M, Potdar AA, Yamashita H, Weidow
B, Cummings PT, Kirchhofer D and Quaranta V: Laminin-332 cleavage
by matriptase alters motility parameters of prostate cancer cells.
Prostate. 71:184–196. 2011. View Article : Google Scholar
|
